Saturday 17 October 2026
Export LEXX’s income statement to Excel — free account
Lexaria Bioscience Corp.
LEXX Healthcare Biotechnology
Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
2.92
0.07
−2.34%
Follow LEXX
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | 0.00 | — |
P/S ratio |
22.60 | — | 32.04 | — | |
P/FCF ratio |
0.00 | — | 0.00 | — | |
P/Operating CF |
(6.04) | — | (8.02) | — | |
P/B ratio |
6.13 | — | 2.80 | — | |
Price to Tangible BV |
6.95 | — | 2.95 | — | |
EV/Sales |
19.90 | — | 22.43 | — | |
EV/EBITDA |
0.00 | — | 0.00 | — | |
EV/Operating CF |
(1.34) | — | (1.30) | — | |
EV/FCF |
(1.33) | — | (1.28) | — | |
Quick Ratio |
1.56 | 3.10 | 24.74 | 9.56 | |
Current Ratio |
2.32 | 3.68 | 26.88 | 10.60 | |
Net Debt/EBITDA |
0.74 | 2.84 | 3.68 | 1.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.11 | 0.00 | 0.07 | 0.00 | |
Operating CF/Net income |
0.98 | 0.62 | 1.49 | 0.82 | |
Capex/Depreciation |
(0.68) | (0.30) | (2.93) | (1.36) | |
Research and Development Expense of Revenue |
1,081.67% | 0.00% | 2,377.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
563.51% | 0.00% | 4,982.50% | 0.00% | |
Intangible Assets out of Total Assets |
0.07 | 0.05 | 0.05 | 0.07 | |
Share Based Compensation of Revenue |
70.52% | 0.00% | 374.50% | 0.00% | |
Graham Net Nets |
0.12 | — | 0.32 | — | |
Graham Number |
0.00 | — | 0.00 | — | |
Earnings Yield |
(73.33%) | — | (66.16%) | — | |
Free Cash Flow Yield |
(66.13%) | — | (54.54%) | — | |
Revenue per Share |
0.14 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(2.20) | (0.69) | (1.33) | (0.99) | |
Capex per Share |
(0.01) | 0.00 | (0.03) | (0.02) | |
Free Cash Flow per Share |
(2.21) | (0.69) | (1.36) | (1.00) | |
Cash per Share |
1.64 | 3.10 | 3.23 | 2.19 | |
Shareholders Equity per Share |
2.17 | 3.17 | 3.81 | 2.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.17 | 3.17 | 3.81 | 2.63 | |
Free Cash Flow |
(2.66) | (0.99) | (2.22) | (1.66) | |
Working Capital |
1.97 | 3.91 | 5.56 | 3.68 | |
Capital Expenditures |
(0.01) | (0.01) | (0.06) | (0.03) | |
Net Current Asset Value |
1.90 | 3.84 | 5.49 | 3.63 | |
EV/EBIT |
0.00 | — | 0.00 | — | |
Capex to Sales |
0.08 | 0.00 | 2.80 | 0.00 | |
Price to Operating Income |
0.00 | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.26 | 0.18 | 0.19 | 0.20 | |
Average Payables |
1.26 | 0.85 | 0.99 | 0.90 | |
Average Assets |
6.52 | 7.92 | 7.58 | 5.76 | |
Average Common Equity |
5.13 | 6.96 | 6.49 | 4.76 |
Columns are period end dates